JP7458977B2 - 免疫刺激性組成物 - Google Patents

免疫刺激性組成物 Download PDF

Info

Publication number
JP7458977B2
JP7458977B2 JP2020531988A JP2020531988A JP7458977B2 JP 7458977 B2 JP7458977 B2 JP 7458977B2 JP 2020531988 A JP2020531988 A JP 2020531988A JP 2020531988 A JP2020531988 A JP 2020531988A JP 7458977 B2 JP7458977 B2 JP 7458977B2
Authority
JP
Japan
Prior art keywords
immunostimulatory
composition
oligonucleotide
nucleic acid
tg4t
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506779A (ja
Inventor
イルグ，トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health GmbH
Original Assignee
Elanco Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Animal Health GmbH filed Critical Elanco Animal Health GmbH
Publication of JP2021506779A publication Critical patent/JP2021506779A/ja
Priority to JP2023134080A priority Critical patent/JP7760560B2/ja
Application granted granted Critical
Publication of JP7458977B2 publication Critical patent/JP7458977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020531988A 2017-12-15 2018-12-07 免疫刺激性組成物 Active JP7458977B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023134080A JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17207746 2017-12-15
EP17207746.3 2017-12-15
EP17207740 2017-12-15
EP17207750 2017-12-15
EP17207750.5 2017-12-15
EP17207740.6 2017-12-15
PCT/EP2018/083956 WO2019115385A1 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023134080A Division JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Publications (2)

Publication Number Publication Date
JP2021506779A JP2021506779A (ja) 2021-02-22
JP7458977B2 true JP7458977B2 (ja) 2024-04-01

Family

ID=66818991

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020531988A Active JP7458977B2 (ja) 2017-12-15 2018-12-07 免疫刺激性組成物
JP2020531982A Active JP7770769B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2020531972A Active JP7273040B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2023128316A Pending JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド
JP2023134080A Active JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020531982A Active JP7770769B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2020531972A Active JP7273040B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2023128316A Pending JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド
JP2023134080A Active JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Country Status (22)

Country Link
US (7) US11932857B2 (enExample)
EP (4) EP3701032A1 (enExample)
JP (5) JP7458977B2 (enExample)
KR (4) KR20250048594A (enExample)
CN (5) CN111447949B (enExample)
AU (5) AU2018385257B2 (enExample)
BR (2) BR112020011815A2 (enExample)
CA (3) CA3085661A1 (enExample)
CL (3) CL2020001560A1 (enExample)
CO (3) CO2020007102A2 (enExample)
CR (1) CR20200260A (enExample)
DK (1) DK3700564T3 (enExample)
DO (3) DOP2020000113A (enExample)
IL (3) IL274975A (enExample)
MX (4) MX2020006243A (enExample)
PE (3) PE20200933A1 (enExample)
PH (3) PH12020550904A1 (enExample)
SG (3) SG11202004773SA (enExample)
TW (2) TW201940192A (enExample)
UY (3) UY38014A (enExample)
WO (3) WO2019115402A1 (enExample)
ZA (1) ZA202004317B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230241196A1 (en) * 2020-01-27 2023-08-03 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
WO2025149000A1 (zh) * 2024-01-09 2025-07-17 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526734A (ja) 2009-05-14 2012-11-01 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 鳥類において増強された免疫応答
JP2014507131A (ja) 2010-12-30 2014-03-27 インターベツト・インターナシヨナル・ベー・ベー 免疫賦活性オリゴデオキシヌクレオチド
JP2017512202A (ja) 2014-02-28 2017-05-18 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
JP3468773B2 (ja) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
AU783118B2 (en) * 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
JP2004501666A (ja) 2000-06-30 2004-01-22 エピゲノミクス　アーゲー 薬理ゲノミクスのメチル化状態分析のための方法及び核酸
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
EP1631576A4 (en) * 2003-06-11 2010-08-25 Idera Pharmaceuticals Inc STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
NZ546475A (en) * 2003-10-30 2008-08-29 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency
AU2004291277A1 (en) * 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
EP1751612B1 (en) * 2004-05-06 2009-02-25 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for the treatment of uveitis
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
JP5473336B2 (ja) 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
JP4847609B2 (ja) * 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
CA2800158C (en) 2010-05-28 2020-07-21 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
PT2654785T (pt) * 2010-12-22 2019-06-25 Bayer Ip Gmbh Resposta imunitária melhorada em espécies bovinas
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
MX2013013801A (es) * 2011-05-26 2013-12-16 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
US20150301058A1 (en) * 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
WO2015010070A1 (en) * 2013-07-19 2015-01-22 National Health Research Institutes Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526734A (ja) 2009-05-14 2012-11-01 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 鳥類において増強された免疫応答
JP2014507131A (ja) 2010-12-30 2014-03-27 インターベツト・インターナシヨナル・ベー・ベー 免疫賦活性オリゴデオキシヌクレオチド
JP2017512202A (ja) 2014-02-28 2017-05-18 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド

Also Published As

Publication number Publication date
AU2018385256B2 (en) 2025-09-25
CA3085657A1 (en) 2019-06-20
RU2020122553A (ru) 2022-01-17
JP2023156485A (ja) 2023-10-24
CN111447949B (zh) 2025-07-11
PH12020550903A1 (en) 2021-05-17
BR112020011838A2 (pt) 2020-11-24
PE20210636A1 (es) 2021-03-23
US20230332162A1 (en) 2023-10-19
SG11202004773SA (en) 2020-06-29
US20230174990A1 (en) 2023-06-08
KR20200098638A (ko) 2020-08-20
TW201936924A (zh) 2019-09-16
EP3694549A1 (en) 2020-08-19
AU2018385257B2 (en) 2025-04-10
JP7760560B2 (ja) 2025-10-27
DOP2020000106A (es) 2020-08-31
CR20200260A (es) 2020-08-01
CN119656298A (zh) 2025-03-21
DK3700564T3 (da) 2025-11-10
SG11202004952UA (en) 2020-06-29
AU2018382419B2 (en) 2025-04-10
CL2020001562A1 (es) 2020-11-06
JP2021506246A (ja) 2021-02-22
BR112020011815A2 (pt) 2020-11-17
WO2019115386A1 (en) 2019-06-20
CA3085661A1 (en) 2019-06-20
TW201936923A (zh) 2019-09-16
JP7770769B2 (ja) 2025-11-17
JP7273040B2 (ja) 2023-05-12
AU2025204678A1 (en) 2025-07-17
EP3700564A1 (en) 2020-09-02
US11932857B2 (en) 2024-03-19
CN111801116B (zh) 2024-11-26
US20210062192A1 (en) 2021-03-04
CN111447949A (zh) 2020-07-24
AU2018385257A1 (en) 2020-06-18
EP3701032A1 (en) 2020-09-02
RU2020122545A3 (enExample) 2022-05-04
US20210170020A1 (en) 2021-06-10
WO2019115402A1 (en) 2019-06-20
TW201940192A (zh) 2019-10-16
US12305173B2 (en) 2025-05-20
CN120519464A (zh) 2025-08-22
CN111801116A (zh) 2020-10-20
MX2025007909A (es) 2025-08-01
CO2020007120A2 (es) 2020-06-19
US11542507B2 (en) 2023-01-03
KR20200099556A (ko) 2020-08-24
DOP2020000113A (es) 2020-08-31
MX2020006244A (es) 2020-09-03
CL2020001561A1 (es) 2020-11-06
JP2021506779A (ja) 2021-02-22
ZA202004317B (en) 2023-05-31
JP2023153970A (ja) 2023-10-18
CL2020001560A1 (es) 2020-11-06
KR102787688B1 (ko) 2025-03-27
IL275086A (en) 2020-07-30
UY38015A (es) 2019-06-28
PH12020550906A1 (en) 2021-05-17
AU2025205082A1 (en) 2025-07-31
US20250215439A1 (en) 2025-07-03
US20200385733A1 (en) 2020-12-10
WO2019115385A1 (en) 2019-06-20
WO2019115386A9 (en) 2020-07-23
MX2020006243A (es) 2020-09-03
JP2021506245A (ja) 2021-02-22
UY38014A (es) 2019-06-28
SG11202004471RA (en) 2020-06-29
AU2018382419A1 (en) 2020-06-04
PH12020550904A1 (en) 2021-05-17
CA3085575A1 (en) 2019-06-20
RU2020122545A (ru) 2022-01-19
CO2020007102A2 (es) 2020-06-19
DOP2020000107A (es) 2020-08-31
EP4647437A2 (en) 2025-11-12
KR20250048594A (ko) 2025-04-09
MX2020006246A (es) 2020-09-03
AU2018385256A1 (en) 2020-06-11
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
BR112020011845A2 (pt) 2020-11-24
IL275217A (en) 2020-07-30
US20240076681A1 (en) 2024-03-07
PE20200933A1 (es) 2020-09-17
PE20210635A1 (es) 2021-03-23
TWI821224B (zh) 2023-11-11
UY38016A (es) 2019-06-28
KR20200098637A (ko) 2020-08-20
IL274975A (en) 2020-07-30
EP3700564B1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
JP7458977B2 (ja) 免疫刺激性組成物
US12168050B2 (en) Compositions comprising a norovirus nucleic acid and methods of use thereof
US20250090652A1 (en) Henipavirus vaccine
KR20160044566A (ko) 호흡기 세포융합 바이러스
EP2867249B1 (en) Toll-like receptors and immunostimulatory oligonucleotides
HK40039985A (en) Immunostimulatory compositions
BR122024026586A2 (pt) Uso de plasmídeo de ácido nucleico e veículo de entrega de lipossomo e oligonucleotídeo imunoestimulatório com motivo de cpg e sequência de oligonucleotídeo enriquecida por guanina na terminação 5'
BR112020011845B1 (pt) Composições imunoestimulatórias e método de preparação das mesmas
TWI900461B (zh) 免疫刺激性寡核苷酸
RU2799523C1 (ru) Иммуностимулирующие композиции
RU2795701C2 (ru) Иммуностимулирующие олигонуклеотиды
HK40039984A (en) Immunostimulatory oligonucleotides

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7458977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150